NIPH Clinical Trials Search

Pancreatic Cancer Screening Using the Enzeavour Assay in Japan

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Pancreatic cancer, Pancreatic neoplasms
Date of first enrollment	10/02/2026
Target sample size	10000
Countries of recruitment
Study type	Interventional
Intervention(s)	Primary screening will use the Enzeavour Pancreatic Cancer Test. Secondary screening will use diagnostic imaging (MRI/MRCP, EUS, or contrast-enhanced CT), selected at the investigator's discretion for each participant.

Outcome(s)

Primary Outcome	Pancreatic Cancer Detection Rate
Secondary Outcome	Positive Predictive Value of the Enzeavour Assay

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	- Asymptomatic adults attending participating facilities for routine health checkups, organized cancer screening, or both - Able to understand the study procedures and provide written informed consent before enrollment
Exclude criteria	- Documented clinical history of pancreatic cancer - Considered unable or unwilling to undergo any required diagnostic imaging modality (MRCP, EUS, or contrast-enhanced CT) after a positive index test result - Any medical, psychological, or social condition that, in the opinion of the principal investigator at each participating site, makes participation inappropriate or compromises study integrity